Karaiskos 2012.

Methods	Parallel randomised trial Method of randomisation: randomised stated, method unclear Method of concealment: open‐label Blinding: open‐label Analysis: no loss to follow‐up
Participants	Location: Greece Setting: outpatients Number of participants: 60 participants at randomisation and all completed the study (mean age 53 years, sex unclear) Treatment group 1: 20 (mean age 51 years, sex unclear) Treatment group 2: 20 (mean age 54 years, sex unclear) Control group: 20 (mean age 52 years, sex unclear) Stroke criteria: ischaemic and haemorrhagic, based on clinical history, physical examination and brain MRI Time since stroke onset at randomisation: within 1 year after stroke Fatigue criteria: participants did not have to have fatigue at recruitment Other entry criteria: clinical diagnosis of depression, within 1 year after stroke Comparability of groups: no significant differences between groups at baseline in demographics, stroke characteristics and fatigue scores
Interventions	Treatment 1 intervention: oral duloxetine, 60 to 120 mg/day Treatment 2 intervention: oral citalopram, 20 to 40 mg/day Treatment 3 intervention: oral sertraline, 50 to 200 mg/day Treatment duration: 3 months Delivered by: unclear
Outcomes	Time for fatigue assessment: baseline, 1 month, 2 months and 3 months after the start of treatment Primary outcome: Hamilton Rating Scale for Depression, Hamilton Rating Scale for Anxiety Secondary outcome: FSS
Notes	Only people with post‐stroke depression were recruited Fatigue was measured as one of the symptoms of depression Funding: no information available
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	High risk	"Open‐label" trial, so participants and medical staff would be aware of what was being used
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not enough information reported
Intention‐to‐treat	Low risk	No loss to follow‐up reported